RxDoctor Payments Data

Aria Hong, MD

Critical Care Medicine · Duarte, CANPI 1396011557

Payments from drug & device makers

$256in general payments, 2019–2025

Across 9 payments — averaging $28.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$76
  • Zambon USA Ltd.$54
  • Paratek Pharmaceuticals, Inc.$41
  • GSK$36
  • Siemens Medical Solutions USA, Inc.$17
  • AstraZeneca$16
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$256100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$256 in reported general payments places this provider in the 40th percentile of 715 critical care medicine providers in California.

See all critical care medicine providers in California

Medicare billing

Part B allowed, 2024
$84,725
Medicare patients
354
Services billed
1,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$25,623
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$11,402
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$10,840
Combivent RespimatIpratropium/Albuterol Sulfate18$9,046
Spiriva RespimatTiotropium Bromide14$8,473
SymbicortBudesonide/Formoterol Fumarate23$6,101
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,768
Advair HfaFluticasone Propion/Salmeterol11$2,874
Wixela InhubFluticasone Propion/Salmeterol12$2,173
Albuterol Sulfate HfaAlbuterol Sulfate33$1,684
Roflumilast13$1,574
Ventolin HfaAlbuterol Sulfate16$1,258
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,203
Levalbuterol Tartrate HfaLevalbuterol Tartrate11$522
Pantoprazole Sodium11$375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$36$36,46354 claims
Boehringer IngelheimCombivent Respimat, Spiriva Respimat, Stiolto Respimat$15$23,28744 claims
AstraZenecaBreztri Aerosphere, Symbicort$16$17,50338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 715 critical care medicine providers in California.

Other critical care medicine in Duarte

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →